modeling and simulation to select oncology dosages - session 2
Published 5 months ago • 956 plays • Length 2:44:03Download video MP4
Download video MP3
Similar videos
-
5:03:04
modeling and simulation to evaluate intrinsic and extrinsic factors
-
24:19
panel on emerging use of modeling and simulation for bioequivalence
-
19:09
regional deposition and systemic pharmacokinetic data of oindps with modeling and simulation
-
4:20:56
meeting of the oncologic drugs advisory committee (odac) day 1
-
5:58
fda d.i.s.c.o.: niraparib in ovarian cancer transcript
-
5:15
fda d.i.s.c.o.: rucaparib in ovarian cancer
-
1:19:13
the right dose for the right patient: challenges and opportunities in dose optimization
-
5:31
fda d.i.s.c.o.: olaparib for gbrcam her2-negative metastatic breast cancer
-
1:15:00
advancing generic drug development: translating science to approval 2023 – day 2 – part 3
-
35:51
orange book exclusivity: part ii - pediatric, orphan, and gain
-
16:24
pbpk modeling and simulation used in assessing be for generic ophthalmic products (19of39)
-
3:37
project optimus: challenge vs. opportunity
-
2:30:15
older adult workshop, march 2021 (part 1 of 2)
-
14:28
quantitative methods and modeling (29of35) complex generics – sep. 25-26, 2019
-
7:01
fda d.i.s.c.o.: burst edition: fda approvals of opdualag (nivolumab and relatlimab-rmbw) for unre...
-
7:31
fda d.i.s.c.o.: fda approval of larotrectinib for advanced malignancies with ntrk gene fusion
-
3:31
fda d.i.s.c.o. burst edition: fda approval of lynparza (olaparib), with abiraterone and prednison...
-
3:21
fda d.i.s.c.o.: intro by dr. richard pazdur
-
48:50
getting the best dose: the clinical pharmacology studies that help achieve this goal